欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (6): 689-695.doi: 10.12092/j.issn.1009-2501.2022.06.013

• 综述与讲座 • 上一篇    下一篇

凝血纤溶系统失衡与特发性肺间质纤维化发病机制及治疗的研究进展

孙莹1,余勤2   

  1. 1兰州大学第一临床医学院,兰州 730000,甘肃;2兰州大学第一医院呼吸与危重症医学科,兰州 730000,甘肃
  • 收稿日期:2022-01-26 修回日期:2022-04-25 出版日期:2022-06-26 发布日期:2022-07-08
  • 通讯作者: 余勤,男,主任医师,博士生导师,研究方向:呼吸系病学。 E-mail: yuq701@163.com
  • 作者简介:孙莹,女,硕士研究生在读,研究方向:呼吸系病学。 E-mail: sunying19960928@163.com
  • 基金资助:
    甘肃省科技计划项目(18YF1FA106)

Research progress on the imbalance of coagulation and fibrinolysis system and the pathogenesis and treatment of idiopathic pulmonary interstitial fibrosis

SUN Ying1, YU Qin2   

  1. 1First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Respiratory and Critical Medicine, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2022-01-26 Revised:2022-04-25 Online:2022-06-26 Published:2022-07-08

摘要: 特发性肺间质纤维化(IPF)是一种进行性间质性肺疾病,其预后比许多癌症都要差,发病机制复杂并且尚未明确。在肺纤维化的动物模型以及IPF的患者中,已证实均存在凝血系统以及纤溶系统的失衡。本文阐述了凝血纤溶系统失衡在IPF中的可能损伤机制,为IPF的治疗提供新思路。

关键词: 特发性肺间质纤维化血小板, 凝血因子, 尿激酶纤溶酶原激活物, 纤溶酶原激活物抑制物

Abstract: Idiopathic pulmonary interstitial fibrosis (IPF) is a progressive interstitial lung disease. Its prognosis is worse than that of many cancers. Its pathogenesis is complex and unclear. The imbalance of coagulation system and fibrinolysis system was confirmed in both animal models of pulmonary fibrosis and patients with IPF. This paper expounds the possible injury mechanism of the imbalance of coagulation and fibrinolysis system in IPF, and provides a new idea for the treatment of IPF. 

Key words: idiopathic pulmonary interstitial fibrosis, platelets coagulation factor, urokinase plasminogen activator, plasminogen activator inhibitor

中图分类号: